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Edited by Lukas HuberAbstract Agonists acting at the CB1 cannabinoid receptor in
N1E-115 neuroblastoma cells were found to activate MAPK
family members with reciprocal eﬃcacies. Thus, HU 210 ro-
bustly increased phosphorylation of ERK1/2 whereas CP
55,940 was more eﬀective in activating JNK. The use of selected
kinase inhibitors conﬁrmed that distinct signalling cascades were
involved in these responses. This reciprocal control of MAPK
activity was correlated with the observation that HU 210- and
CP 55,940-mediated regulations of tyrosine hydroxylase gene
expression were respectively impaired by MEK and JNK inhib-
itors. These data indicate that complex interactions of the CB1
receptor with intracellular signalling partners controlling MAPK
activities may explain the apparent disparities in cellular re-
sponses to functional selective agonists.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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In the central nervous system, the CB1 cannabinoid (CB1)
receptor mediates most of the behavioural eﬀects of D9-THC,
the major psychoactive component of Cannabis sativa, through
activation of Gi/o-type G proteins. Accordingly, inhibition of
adenylyl cyclase is the predominant short-term response char-
acterised for D9-THC and other ligands activating this recep-
tor. This predominant coupling also supports the inhibition
of voltage-gated Ca2+-channels as well as the increase in G
protein-coupled inwardly-rectifying K+ currents. Analysis of
downstream signallings also evidenced the recruitment of
mitogen activated protein kinases (MAPK) by cannabinoid
agonists (see [1] for review). Among the diﬀerent members of
the MAPK family, extracellular signal-regulated kinase 1
and 2 (ERK1/2) [2], c-Jun N-terminal kinase (JNK) and p38
MAPK [3] appear to be regulated by CB1 receptor through
several signalling pathways. Yet, the complexity of cellular re-
sponses is also inﬂuenced by the model where the receptor is
studied. Thus, variables such as the nature of adenylyl cyclase*Corresponding author. Fax: +32 2 764 5460.
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doi:10.1016/j.febslet.2008.10.022isoforms that are expressed [4], the existence of constitutive
eﬀector activity and the subtype of Gi/o-type G proteins that
couple with CB1 receptor [5,6] may explain paradoxical re-
sponses such as increased cAMP accumulation [7], activation
of calcium channel [8] or inhibition of ERK1/2 [9].
Considering the multiplicity of signals triggered by cannabi-
noid agonists, the CB1 receptor represents an attractive model
to study the biochemical mechanisms inﬂuencing the pharma-
codynamic properties of distinct ligands acting at single G pro-
tein-coupled receptors. As diﬀerent conformations presumably
support distinct couplings of the receptor with speciﬁc G pro-
teins and intracellular eﬀectors, unrelated agonists may ulti-
mately trigger multiple responses with independent eﬃcacies
[10]. Indeed, both HU 210 and CP 55,940 were described as
partial agonists in regulating transient intracellular Ca2+ mobi-
lisation [11] whereas in guanylyl nucleotide binding and aden-
ylyl cyclase assays, these compounds are commonly
considered as full agonists. In addition CP 55,940 was also re-
ported as a partial agonist for inhibition of [Ca2+]i spiking [12].
Consistent with the low eﬃcacy sometimes reported for CP
55,940, we recently evidenced that the AP-1-dependent modu-
lation of gene transcription by HU 210 was antagonised by
CP 55,940 [13]. In the present study, we further characterised
the pharmacodynamic proﬁles of HU 210 and CP 55,940 by
measuring the activation of diﬀerent MAPK family members
in N1E-115 neuroblastoma cells. Our data indicate that HU
210 robustly phosphorylates ERK1/2 while CP 55,940 was
more eﬀective in activating JNK, suggesting the existence of
speciﬁc signalling pathway eﬃcacies for these potent agonists
of the CB1 receptor.2. Materials and methods
2.1. Materials
The gene reporter plasmid pTH250-Luc in which the ﬁreﬂy lucifer-
ase sequence is cloned under the control of the TH gene promoter
was provided by Dr. M. Najimi [14]. pRL 138 encoding renilla lucifer-
ase and used for standardisation of transfection procedures was ob-
tained from Dr. E. Pierreux [15]. The CB1 receptor inverse agonist/
antagonist SR 141716A was generously given by Dr. Barth (Sanoﬁ-
Synthe´labo Research, Montpellier, France). HU 210 and CP 55,940
were purchased from Tocris Cookson (Bristol, UK) and all kinase
inhibitor tested were from Sigma (Boornem, Belgium).
2.2. Cell culture
All cell culture media and supplements were obtained from
Invitrogen (Merelbeke, Belgium). Mouse neuroblastoma N1E-115 cells
were grown in Dulbeccos MEM/NUT mix F-12 medium supple-
mented with 10% foetal calf serum, 100 UI/ml penicillin, 100 lg/mlblished by Elsevier B.V. All rights reserved.
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ducted in the same culture medium. Cells were cultured at 37 C in
an atmosphere of humidiﬁed air and 5% CO2.
2.3. Immunoblotting studies
At the end of incubation with drugs, cells cultured in 6-well plates
were washed with phosphate buﬀer saline (PBS, Invitrogen), scrapped
and collected by brief centrifugation. Pelleted cells were resuspended in
lysis buﬀer containing 50 mM HEPES, 50 mM KF, 1 mM Na3PO4,
1 mM EDTA, 1 mM EGTA, 0.5% 2-mercaptoethanol, 5 mM b-glycer-
olphosphate, 5 mM Na4P2O7, 1 mM phenylmethylsulphonyl ﬂuoride,
100 lM Na3VO4, 1% Triton X-100, protease inhibitor complete mini
EDTA (Roche, Vilvoorde, Belgium) and phosphatase inhibitor cock-
tail (Sigma). After 30 min incubation, cell lysate was centrifuged to re-
move cell debris and protein content of the supernatant was
determined. All these procedures were carried out at 0–4 C. Protein
extracts were diluted in 5· loading buﬀer (250 mM Tris–HCl,
500 mM dithioerythritol, 10% sodium dodecylsulfate (SDS), 50% glyc-
erol, 0.5% bromophenol blue). Samples (respectively, 20 or 40 lg for
ERK1/2 and JNK detection) were boiled for 5 min, separated on a
12% SDS–polyacrylamide gel and transferred to nitrocellulose mem-
brane. The blots were blocked for 1 h in TBST buﬀer (25 mM Tris–
HCl, pH 7.4, 125 mM NaCl, and 0.5% Tween-20) containing 5%
non-fat milk and then incubated with ERK1/2, JNK-1, or p38 MAPK
phospho-speciﬁc antibodies (phospho-MAPK family antibody sam-
pler kit from Cell Signalling Technology, Bioke´, Leiden, The Nether-
land), overnight at 4 C in the same buﬀer. The blots were washed in
TBST buﬀer, and speciﬁc immunoreactive proteins revealed with a per-
oxydase linked anti-rabbit IgG were detected using the SuperSignalFig. 1. HU 210 and CP 55,940 increase ERK1/2 phosphorylation in N1
antibodies recognising either speciﬁc residues of phosphorylated ERK1/2 or
induced by the agonists (100 nM). B, C and D, respectively illustrate the inﬂue
the PI3K inhibitor wortmannin (0.2 lM) and the PKC inhibitor GF109203X
the cells to HU 210 and CP 55,940 (both at 100 nM). Responses were quantiﬁ
from at least three independent experiments and normalised for the signal co
expressed in percentage of control (vehicle treated cells). *P < 0.05, **P < 0.01
the inhibitor only.West Pico Chemiluminescent Substrate System (Pierce, Erembodegem,
Belgium). The blots were then stripped and re-probed with antibodies
that recognise both the phosphorylated and non phosphorylated forms
of ERK1/2, JNK-1, or p38 MAPK (same kit as above, from Cell Sig-
nalling Technology). Relative amounts of protein were quantiﬁed by
scanning densitometry using the software Image Master (Pharmacia
Biotech Benelux, Roosendael, The Netherlands).
2.4. Transient transfection and luciferase assay
N1E-115 cells were cotransfected with pTH250-Luc and pRL 138,
using the phosphate co-precipitation method as previously described
[16]. For drug treatments, transfected cells were washed with PBS
and incubated with 100 nM HU 210 or 100 nM CP 55,940 for 5 h in
fresh medium. When indicated, SR 141716A was added 5 min prior
the agonists. When testing the inﬂuence of kinase inhibitors, these were
added 1 h beforehand at concentrations achieving maximal eﬃcacy
and target selectivity [17–23].
At the end of the 5 h incubation period, cells were lysed by addition
of 100 ll of passive lysis buﬀer supplied in the Dual Luciferase Repor-
ter Assay System (Promega, Leiden, The Netherlands). Fireﬂy lucifer-
ase reporter activity was normalised for the renilla luciferase activity.
Respective measurement of light emission was determined according
to the manufacturers instructions with a TD20/20 luminometer (Turn-
er design, Sunnyvale, CA, USA).
2.5. Data analysis
Unless otherwise stated, data presented in the text and ﬁgures were
expressed as mean percentages ± S.E.M. of the corresponding values
obtained with cells treated with vehicle alone (DMSO diluted in cultureE-115 cells. Typical immunoblotting analyses of cells extracts using
total ERK1/2. A shows the time-course of ERK1/2 phosphorylation
nce of the CB1 selective antagonist/inverse agonist SR 141716A (1 lM),
(0.25 lM) on ERK1/2 phosphorylation induced by 15 min exposure of
ed by densitomeric analysis of phospho-ERK1/2 immunoreactive bands
rresponding to total ERK1/2. Data shown are mean values with SEM
, relative to vehicle treated cells, #P < 0.05 relative to cells treated with
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quantiﬁed using densitometry and normalized against signal corre-
sponding to the total amount of the selected kinase. Mean percentages
were obtained from at least three independent experiments. One-way
analyses of variance (ANOVA) with repeated measures were per-
formed using Graph Pad prism software (San Diego, CA). Post hoc
analysis for pair-wise comparisons was carried out by Tukeys test.3. Results
3.1. Cannabinoid-mediated ERK1/2 phosphorylation
Semi-quantitative analysis of ERK1/2 activation in N1E-115
cells was speciﬁcally examined by comparing immunoreactive
signals detected with antibodies recognising either total ERK
1/2 or the phosphorylated, activated form of ERK1/2. Immu-
noblotting studies revealed that the exposure of N1E-115 neu-
roblastoma cells to either HU 210 (100 nM) or CP 55,940
(100 nM) resulted in a transient phosphorylation of ERK1/2
with a peak response after 15 min treatment for both agonists
(Fig. 1A). Inductions measured at this time point revealed con-
centration-dependent responses (Table 1). When both agonists
were used at maximal eﬀective concentrations, the amplitude
of the response was markedly diﬀerent and the levels of phos-
pho-ERK1/2 appeared signiﬁcantly higher when using HU 210
as compared to CP 55,940. The selective inverse agonist/antag-
onist SR 141716A (1 lM) totally inhibited the responses to
both agonists, demonstrating that ERK1/2 phosphorylation
was strictly dependent on the activation of the CB1 receptor
(Fig. 1B). To characterise the signalling pathways involved in
CB1 receptor mediated ERK1/2 activation, N1E-115 cells were
pre-incubated for 1 h with diﬀerent kinase inhibitors (Fig. 1C–
D). HU 210-induced ERK1/2 phosphorylation was signiﬁ-
cantly reduced using the phosphatidyl inositol 3-kinase
(PI3 K) inhibitor wortmaninn (0.2 lM) whereas the PKC
inhibitor GF109203X abolished this response (0.25 lM). The
opposite was observed when examining the response to CP
55,940 as wortmaninn totally suppressed ERK1/2 phosphory-
lation induced by this agonist whereas GF109203X was inef-
fective. Hence, inhibiting PKC tended to amplify the
response to CP 55,940.
3.2. Cannabinoid-induced JNK phosphorylation
The inﬂuence of the cannabinoid agonists on JNK phos-
phorylation was examined using antibodies speciﬁcally raised
against phosphorylated p46 and p54 JNK. Both HU 210
(100 nM) and CP 55,940 (100 nM) increased the level of phos-
pho-JNK (Fig. 2A). As maximal responses were measuredTable 1
Concentration-dependency of cannabinoid-mediated MAPK phorsphorylati
0.1 nM 3.16 nM
ERK1/2
HU 210 130.8 ± 15.3 202.4 ± 11.6
CP 55,940 91.75 ± 4.2 122.3 ± 6.3
JNK
HU 210 100.5 ± 15.1 132.6 ± 10.5
CP 55,940 148.5 ± 20.4 187.7 ± 35.5
Cells were exposed for 15 min (ERK1/2) or 5 min (JNK) to vehicle or i
immunoblotting analyses for phospho-MAPK and densitometric quantiﬁca
experiments) were normalised for the signal corresponding to total MAPK a
cells) arbitrarily set at 100%. *P < 0.05, **P < 0.01, relative to vehicle treatedafter 5 min of exposure to the agonists we further evaluated
the concentration-dependent eﬀects of either HU 210 or CP
55,940 on cells treated during 5 min (Table 1). At variance with
results referring to ERK1/2 phosphorylation, the inﬂuence of
HU 210 on JNK phosphorylation appeared modest as com-
pared to CP 55,940.Nevertheless, both responses were sup-
pressed in the presence of SR 141716A (Fig. 2B). In the
presence of wortmaninn, the responses were totally inhibited
(Fig. 2C) suggesting the involvement of PI3K in both HU
210 and CP 55,940-mediated JNK phosphorylation. Notewor-
thy, the basal level of phospho-JNK was also reduced in cells
exposed to wortmaninn.
3.3. Lack of cannabinoid-mediated p38 MAPK phosphorylation
Contrasting with previous studies reporting on the cannabi-
noid-mediated activation of p38 MAPK [3], neither HU 210
nor CP 55,940 were found to alter phospho-p38 MAPK levels
in N1E-115 cells (Fig. 3A). Yet, hydrogen peroxide (5 mM),
used as a positive control robustly increased p38 MAPK phos-
phorylation (Fig. 3B).
3.4. Involvement of MAPK dependent signallings in the
modulation of gene transcription by cannabinoid agonists
We previously reported on the reciprocal regulation of tyro-
sine hydroxylase (TH) gene expression by the cannabinoid
agonists HU 210 and CP 55,940. Since these agonists diﬀeren-
tially inﬂuenced the activity of MAPK and considering that re-
lated signallings are frequently involved in the modulation of
gene transcription, we evaluated inﬂuence of diﬀerent MAPK
inhibitors on the regulation of TH expression by these cannab-
inoid ligands. Using a luciferase reporter assay, we observed
that the MAP/ERK kinase (MEK1/2) inhibitors, U0126
(5 lM) and PD98059 (25 lM) reduced basal activity of the
TH gene promoter while SP600125 (10 lM), an inhibitor of
JNK, signiﬁcantly increased this basal activity.
In agreement with its strong inﬂuence on ERK1/2, the regu-
lation of the TH gene promoter by HU 210, was inhibited by
U0126 and PD98059, as a consequence of the indirect block-
ade of ERK1/2 by these MEK1/2 inhibitors. In contrast,
SP600125 and SB202190 (respectively inhibiting JNK and
p38 MAPK, 10 lM) failed to suppress HU 210-mediated
responses (Fig. 4). On the other hand, U0126 and PD98059
only slightly reduced CP 55,940-mediated activation of the
TH gene promoter. Yet, this response to CP 55,940 was com-
pletely abolished with SP600125, suggesting that the regulation
of the TH gene promoter activity in N1E-115 cells involves
both ERK1/2- and JNK-dependent signalling. The speciﬁcon.
100 nM 1 lM
270.8 ± 38.1** 300.6 ± 25.0**
151.6 ± 6.2** 150.6 ± 6.9**
176.3 ± 19.5* 154.9 ± 16.6
439.3 ± 79.4** 375.2 ± 77.8*
ncreasing concentrations of cannabinoid agonists before extraction,
tions. Responses (mean values with S.E.M. from three independent
nd expressed in percentages relative to control values (vehicle treated
cells.
Fig. 2. HU 210 and CP 55,940 increase JNK phosphorylation in N1E-115 cells. Typical immunoblotting analyses of cells extracts using antibodies
recognising either speciﬁc residues of phosphorylated JNK or total JNK. A shows the time-course of JNK phosphorylation induced by the agonists
(100 nM). B and C, respectively, illustrate the inﬂuence of the CB1 selective antagonist/inverse agonist SR 141716A (1 lM) and the PI3K inhibitor
wortmannin (0.2 lM) on JNK phosphorylation induced by 15 min exposure of the cells to HU 210 and CP 55,940 (both at 100 nM). Responses were
quantiﬁed by densitomeric analysis of phospho-JNK immunoreactive bands from at least three independent experiments and normalised for the
signal corresponding to total JNK. Data shown are mean values with SEM expressed in percentage of control (vehicle treated cells). *P < 0.05,
**P < 0.01, relative to vehicle treated cells, # <0.05 relative to cells treated with the inhibitor only.
Fig. 3. HU 210 and CP 55,940 do not induce p38 MAPK phosphor-
ylation in N1E-115 cells. Immunoblotting analysis performed using
antibodies recognising either speciﬁc residues of phosphorylated p38
MAPK or total p38 MAPK. (A) The blots show the lack of p38
MAPK phosphorylation after exposure to the agonists (100 nM) for
up to 45 min. (B) The assay was validated using H2O2 as positive
control for p38 MAPK phosphorylation. The experiments were
repeated three times independently with similar results.
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bition for HU 210 and CP 55,940, respectively) when blocking
PI3 K activation using either wortmannin or LY294002
(25 lM). Finally, conﬁrming the absence of p38 MAPK regu-
lation by cannabinoids in these cells, the response to HU 210
and CP 55,940 was not changed in the presence of SB202190.4. Discussion
The classical MAPK pathway was originally described as a
triple protein kinase cascade (Raf/MEK/MAPK) which is indi-
rectly activated by tyrosine kinase receptors through their
interaction with small monomeric G proteins. Presently, evi-
dence is accumulating which indicates that G protein-coupled
receptors also recruit MAPK through an intricate signalling
network. With respect to cannabinoid receptors, PI3 K was
frequently described as a key signalling intermediate in the
activation of MAPK [3,9,24]. Yet, in N1E-115 cells, activation
of the constitutively expressed CB1 receptor by WIN 55,212-2
induced ERK1/2 phosphorylation through Gi/o-dependent
inhibition of PKA pathway [25]. Unexpectedly, our prelimin-
ary experiments evidenced that in the same cell line, PKA inhi-
bition failed to prevent HU 210 and CP 55,940 mediated
increases in phospho-ERK1/2 level (data not shown). Besides,
wortmannin was eﬀective in reducing cannabinoid-mediated
Fig. 4. Characterisation of cell signallings involved in cannabinoid-
mediated regulation of TH gene promoter. Luciferase activity was
examined in N1E-115 cells carrying pTH250-Luc, pre-treated for 1 h
with vehicle or with kinase inhibitors and subsequently exposed for 5 h
to HU 210 or CP 55,940 (both at 100 nM). Results (mean values with
S.E.M. from three independent experiments performed in triplicate)
are given as the percentages of relative luciferase activity (ﬁreﬂy
luciferase relative to Renilla luciferase) relative to control cells.
Numbers indicated next to each bar correspond to the same data
expressed as percentage of activity when testing the inhibitor alone.
*P < 0.05, **P < 0.01 relative to vehicle treated cells, #P < 0.05 relative
to cells treated with the inhibitor alone.
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to activate ERK1/2 cascade in these cells. Nevertheless, a ﬁrst
set of key observations is that HU 210 increased phosphoryla-
tion of ERK1/2 much more eﬃciently than CP 55,940, and
that the response to HU 210 was only partially suppressed with
wortmannin, suggesting the involvement of diﬀerent signalling
intermediates. Indeed, inhibition of PKC completely abolished
HU 210- but not CP 55,940-mediated increase in phospho-
ERK1/2 levels. These data corroborate our previous studies
demonstrating that unrelated ligands stimulate distinct trans-
duction pathways upon interaction with the CB1 receptor.
Consistent with a PI3K-dependent activation of JNK de-
scribed by Rueda [3], we observed a cannabinoid-induced in-
crease in JNK phosphorylation that was inhibited by
wortmannin. Noteworthy, PKA and PKC inhibitors failed to
reduce JNK phosphorylation mediated by both cannabinoid
agonists (data not shown). Finally, while several studies have
evidenced a cannabinoid-mediated activation of p38 MAPK
[3,26,27,28], neither HU 210 nor CP 55,940 appeared to signif-
icantly increase phospho-p38 MAPK level in N1E-115 neuro-
blastoma cells.
Frequently used as reference agonists for cannabinoid recep-
tors, HU 210 and CP 55,940 are generally characterised as full
CB1 receptor agonists in guanylyl nucleotide binding [29–31]
and cAMP accumulation [31–33] assays, displaying similar
potencies and eﬃcacies. At variance, focusing on ERK1/2
and JNK pathways, we herein evidence that these agonistsshow distinct and reciprocal inﬂuences on MAPK activation.
Concentration-dependent characterisations of ERK and JNK
phosphorylation clearly suggest an inverse rank order of eﬃ-
cacy for HU 210 and CP 55,940 when examining the diﬀerent
signalling pathways. In addition, the responses were systemat-
ically antagonised using SR 141716A, conﬁrming that the dif-
ference in eﬃcacy purely reﬂects the concept of agonist-
selective traﬃcking (Kenakin 1995), currently also referred as
functional selectivity [10]. Noteworthy, while up to now this
concept was poorly illustrated at the level of CB1 signalling,
several previous studies already reported agonist-selective cou-
pling of the CB1 receptor [1,7,34]. Furthermore, it was recently
demonstrated that distinct agonist-bound CB1 receptor con-
formations exhibit diﬀerent aﬃnities and eﬃcacies towards
the Gi1 type G protein [35]. This is consistent with the hypoth-
esis that functional selectivity arises though agonist-selective
stabilisation of diﬀerent receptor conformations and subse-
quent selective interactions with diﬀerent G proteins.
Activated MAPK participate in the regulation of gene
expression through the phosphorylation of transactivating do-
mains of several transcription factors. Thereby, endogenous
cannabinoids inﬂuence target genes involved in regulation of
cell proliferation, diﬀerentiation and death [36,37]. In particu-
lar, there is emerging evidence that cannabinoids may repre-
sent neuroprotective agents through regulation of PI3K/Akt
survival pathways [38,39]. Supporting a role of ERK signalling
in the survival responses, connections between PI3K/Akt and
Raf/ERK pathways were previously suggested [24]. Further-
more, inhibition of ERK activity was shown to participate in
cannabinoid-mediated cell apoptosis [40,41]. On the other
hand, several studies reported that cannabinoids induce apop-
tosis through activation of JNK-dependent pathways [42–44].
In this respect, one could propose that diﬀerent cannabinoid
ligands may exhibit opposite inﬂuences on cell death/survival
signallings through preferential activation of diﬀerent MAPK
family members.
Besides, the present data indicate that exogenous cannabi-
noid agonists could distinctly regulate gene transcription, lead-
ing to unexpected outcomes. Indeed we previously evidenced
that the CB1 receptor operates a complex control of TH
expression through an agonist-selective regulation of intracel-
lular signallings [16]. Accordingly, a second key ﬁnding of this
work is the demonstration that HU 210-mediated reduction of
TH gene promoter activity is regulated through ERK1/2
dependent signalling whereas CP 55,940-induced increased in
the activity of the same promoter is supported by the JNK cas-
cade. In addition, inhibition of PI3K which acts upstream of
both ERK1/2 and JNK reduced the cannabinoid-mediated
regulation of TH gene expression. As activation of MAPK
family members is commonly reported to up-regulate the
expression of TH, the reduced gene transcription obtained
with HU 210 remains enigmatic. Likewise, decreased tran-
scriptional activity induced by CB1 receptor agonists was re-
cently reported and assigned to novel mechanism involving a
MAPK-dependent methylation of speciﬁc DNA sequences
[28]. Noteworthy, the eﬀect of HU 210 on the TH gene pro-
moter was only partially blocked with wortmannin, conﬁrming
that the activation of ERK1/2 involved the modulation of
additional eﬀectors. Also consistent, inhibition of PI3K with
wortmaninn substantially increased the basal activity of the
promoter, indicating that a constitutive activity of PI3K exert
a negative inﬂuence on TH gene transcription.
3866 B. Bosier et al. / FEBS Letters 582 (2008) 3861–3867In conclusion, this study provides compelling evidence that
HU 210 and CP 55,940 exhibit reversed order of eﬃcacy in
the activation of distinct members of the MAPK family regu-
lated by the CB1 receptor. In addition, focusing on the regula-
tion of TH which constitutes a putative target of cannabinoids
in adrenergic cells, this study reveals that the diﬀerential acti-
vation of eﬀectors may selectively inﬂuence the regulation of
downstream responses. Together these ﬁndings emphasize on
the importance to systematically delineate the complex signal-
ling cascades associated with a given G protein-coupled recep-
tor to explain overall cellular responses to interacting ligands.
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